IBII

iShares iBonds Oct 2032 Term TI

Bearish Trend

Near 52W High

$25.36$0.02 (-0.08%)

Loading Chart...

Institutional Signal // Day Trade Edge:Neutral / No Active Setup Today

Scan Active Universe on Day Trade Edge

Key Statistics

Market Cap—

Forward P/E—

EPS (TTM)—

52-Week Return-3.73%

50-Day Moving Avg$25.42

200-Day Moving Avg$25.86

Volume Today24.43K

Avg Volume19.2K

Day Range$25.36 – $25.39

52-Week Range$25.14 – $26.55

Open Price$25.39

Previous Close$25.38

Company Profile

Description

The index consists of inflation-protected public obligations of the U.S. Treasury, commonly known as “TIPS,” that are scheduled to mature between January 1, 2032 and October 15, 2032, inclusive. The fund will invest at least 80% of its assets in the component securities of the underlying index.

SEC Filings

EDGAR Filings

Exchange Listing

Nasdaq.com

Company Profile

Description

SEC Filings

EDGAR Filings

Exchange Listing

Nasdaq.com

IBII

Key Statistics

Company Profile

Company Profile

Recent News

Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer

Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.

Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy

Recent News

Company Profile

Recent News

Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer

Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.

Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy